Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Retatrutide showing promise in obesity (and type 2 diabetes)

Doggrell, Sheila A · 2023 · Expert Opinion on Investigational Drugs

Abstract

INTRODUCTION: Obesity is a major risk factor for cardiovascular disease, diabetes, osteoarthritis, and some cancers. Retatrutide stimulates Glucagon-like peptide 1 (GLP-1), Glucose-dependent insulinotropic polypeptide (GIP) receptors, and glucagon receptors, and is being developed for the treatment of obesity and type 2 diabetes. AREAS COVERED: A phase 2 clinical trial of retatrutide (LY3437943) in the treatment of obesity. The primary end point was percentage change in weight from baseline to 24 weeks, which ranged from -7.2% to -~18% as the dose of retatrutide increased from 1 mg to 12 mg. The most frequent adverse events were gastrointestinal (nausea, diarrhea, vomiting). EXPERT OPINION: The results for retatrutide in phase 2 for obesity (and diabetes) are mostly encouraging. Consistent with being a GLP-1 receptor agonist, heart rate was increased by up to 6.7 beats/min by retatrutide, which may be detrimental and offset some of the benefits of weight loss. Presumably, retatrutide is being developed as a challenger to the recently developed weight loss medicines; semaglutide and/or tirzepatide. Thus, comparator studies are needed between retatrutide and these drugs, but none are ongoing and, in my opinion, this lack is a major omission in the development of retatrutide.

Overview

Integrity signals

Registry

Crossref · 10.1080/13543784.2023.2283020

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 15 references

Cited by

See all 16

Metadata

Authors
Doggrell, S. A.
Affiliations
Griffith University (AU)
Corresponding author
Doggrell, Sheila A
Venue
Expert Opinion on Investigational Drugs
Published
2023-11-02
Volume
32
Issue
11
Pages
997-1001
ISSN
  • 1354-3784 (ISSN-L)
  • 1744-7658
OpenAlex
W4388565841
Cited by
16
References
15
Citations by year
2026: 4 · 2025: 5 · 2024: 7
FWCI
2.50
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Investigational Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
retatrutide, obesity, type 2 diabetes, GLP-1 receptor agonists, GIP receptor, glucagon receptor, weight loss, adverse events, heart rate, semaglutide, tirzepatide, anti-obesity drugs
MeSH terms
Glucagon-Like Peptide-1 Receptor, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Obesity, Risk Factors, Weight Loss, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Retatrutide showing promise in obesity (and type 2 diabetes). https://app.cochat.ai/papers/10.1080/13543784.2023.2283020
The paper
Doggrell, S. A. (2023). Retatrutide showing promise in obesity (and type 2 diabetes). Expert Opinion on Investigational Drugs. https://doi.org/10.1080/13543784.2023.2283020

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.